Eganelisib (IPI-549)lipid nanoparticle formulation

We can offer a discount on bulk orders. Please contact our sales team for further inquiry.

Product Infomation

Product Name	Eganelisib (IPI-549)lipid nanoparticle formulation
Catalog Number	LNP-013
Size	10 mg; 20 mg; 50 mg
Alias	Eganelisib (IPI-549)LNP; IPI-549 nano-lipid nanoparticle (WNX5.2 Prescription)
Appearance	Milky white to light milky yellow homogeneous suspension
Solubility	It can be dispersed in physiological buffer (such as PBS)or 5% glucose solution to form a stable colloidal dispersion system
Description	Eganelisib (IPI-549)LNP is a specialized nano-lipid nanoparticle formulation of the selective PI3K-γ inhibitor eganelisib (IPI-549), which is encapsulated using the optimized formula WNX5.2. As a highly selective PI3K-γ oral inhibitor, eganelisib can enhance the anti-tumor immune response by regulating the function of immunosuppressive myeloid cells in the tumor microenvironment, showing synergistic potential in combined immune checkpoint inhibitor research. However, its limited oral bioavailability, unsatisfactory distribution in the body, and insufficient targeting of the tumor immune microenvironment limit its full effect.
Applications	Research on tumor targeting and efficacy optimization of PI3K-γ inhibitors
Storage	4°C, protected from light
Purity	95%+
Shelf Life	1 Year
Shipping Condition	Low temperature transport

Online Inquiry